{"commentary":{"count":30,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":12,"podcast":12,"x_thread":6},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02425891\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT02425891","nct_id":"NCT02425891","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02425891. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","label":"Atezolizumab Plus Nab-Paclitaxel","type":"EXPERIMENTAL"},{"description":"Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","label":"Placebo Plus Nab-Paclitaxel","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2021-08-31","type":"ACTUAL"},"conditions":["Triple Negative Breast Cancer"],"enrollment":{"count":902,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody","type":"DRUG"},{"name":"Nab-Paclitaxel","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"last_update":"2022-07-19","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2020-04-14","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) in All Randomized Participants","timeFrame":"Baseline up to approximately 34 months"},{"measure":"PFS According to RECIST v1.1 in Participants With Detectable Programmed Death-Ligand 1 (PD-L1)","timeFrame":"Baseline up to approximately 34 months"},{"measure":"Overall Survival (OS) in All Randomized Participants","timeFrame":"Baseline until death due to any cause (up to approximately 58 months)"},{"measure":"OS in Participants With Detectable PD-L1","timeFrame":"Baseline until death due to any cause (up to approximately 58 months)"}],"references":[{"citation":"Li M, Yang B. Prognostic Value of NUSAP1 and Its Correlation with Immune Infiltrates in Human Breast Cancer. Crit Rev Eukaryot Gene Expr. 2022;32(3):45-60. doi: 10.1615/CritRevEukaryotGeneExpr.2021040248.","pmid":"35695609","type":"DERIVED"},{"citation":"Wang H, Ma H, Sove RJ, Emens LA, Popel AS. Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer. J Immunother Cancer. 2021 Feb;9(2):e002100. doi: 10.1136/jitc-2020-002100.","pmid":"33579739","type":"DERIVED"},{"citation":"Adams S, Dieras V, Barrios CH, Winer EP, Schneeweiss A, Iwata H, Loi S, Patel S, Henschel V, Chui SY, Rugo HS, Emens LA, Schmid P. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Ann Oncol. 2020 May;31(5):582-589. doi: 10.1016/j.annonc.2020.02.003. Epub 2020 Feb 20.","pmid":"32178964","type":"DERIVED"},{"citation":"Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Investigators. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Jan;21(1):44-59. doi: 10.1016/S1470-2045(19)30689-8. Epub 2019 Nov 27.","pmid":"31786121","type":"DERIVED"},{"citation":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Trial Investigators. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20.","pmid":"30345906","type":"DERIVED"}],"start_date":{"date":"2015-06-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)","url":"https://clinicaltrials.gov/study/NCT02425891"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02425891"}